Roche v. Biosite
This article was originally published in The Gray Sheet
Executive Summary
San Diego manufacturer Biosite believes patent infringement allegations filed Nov. 9 by Roche in Indianapolis federal court are without merit. The suit references two Roche U.S. patents covering a biosensing meter and a device used for separating plasma or serum from whole blood. Biosite markets the Triage line of drugs-of-abuse assays, cardiac marker test kits and B-type natriuretic peptide (BNP) point-of-care hormone diagnostic tests...
You may also be interested in...
Biosite sues Roche
San Diego firm files complaint in California district court alleging Roche Diagnostics is infringing on two patents related to methods for measuring cardiac troponin forms, according to a Nov. 30 release. The filing marks the second suit Biosite has brought against Roche in recent months. On Nov. 9, the firm brought patent infringement allegations in Indianapolis federal court regarding its biosensing meter and a device used for separating plasma or serum from whole blood (1"The Gray Sheet" Nov. 22, 2004, In Brief)...
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.